PO-92 QZU® (Kudzu e.s.: 200 mg of which Isoflavones: 80 mg and Puerarin: 60 mg; ComplexZyme vegan®: 40 mg) in the prophylaxys of migraine without aura: a retrospective observational study
Ennio Pucci,1 Ludovica Pucci,2 Alberto Vercesi3 | 1Department of Nervous System and Behavioral Sciences, University of Pavia; 2Nutritional biologist, Master in Nutritional and Clinical Dietetics, University of Pavia, Italy; 3Scientific Advisor
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: Kudzu (Pueraria montana lobata) is a wild climbing plant native to Asia belonging to the Fabaceae family. The Kudzu roots are rich in isoflavones that stimulate the production of dopamine by the brain and act on neurotransmitters such as serotonin, GABA and glutamate. Use QZU cp in the treatment of migraine with and without aura, determine its efficacy, dosage and tolerability.
Methods: Between January and June 2025, 18 patients with migraine with and without aura, were treated with QZU® 1 cps/day for 2 months, recruited in various neurological and general medicine outpatient facilities; all patients filled out the diary and the data collection form (ICHD-III criteria). Patients were evaluated at baseline and after 2 months of treatment regarding the number of attacks, migraine days and VAS (Visual Analogue Scale): data on efficacy and tolerability were collected. Patient characteristics: 16 females and 2 males; mean age 37 (18-58); 26 patients with migraine without aura and 2 with aura. At baseline in the total population the mean number of attacks/month was 6.7 (4-10), migraine days/month 13.5 (7-21) and mean VAS 7.8 (6-10).
Results: QZU® was well tolerated: on a numeric scale of 1-10 the average score was 9.5; patient compliance was optimal, no product-related side effects were reported and no weight gain occurred in patients. A clear improvement in patients' asthenia was noted. As for efficacy, at the end of treatment, in the total population all analyzed parameters significantly improved: the average number of crises/month was 2.8 (1-4), headache days / month 6 (2-14) and the average VAS 3.2 (2-5).
Conclusion: In recent years there has been a growing interest in the use of nutraceuticals for migraine prevention. Our study has clearly demonstrated the benefits, safety and good tolerability of QZU® in migraine prophylaxis confirming the data obtained in previous studies.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.